Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Histatin for Corneal Wound Healing and Ocular Surface Disease

a corneal wound and histatin technology, applied in the field of wound healing and disease healing, can solve the problems of inability to translate into a finding for therapeutic or clinical use, all done in vitro, etc., and achieve the effect of accelerating the healing of ocular surface diseas

Inactive Publication Date: 2013-11-21
VISUS THERAPEUTICS INC
View PDF2 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a method for treating corneal wounds and ocular surface disease by administering a therapeutic amount of a peptide fragment of histatin. This peptide can be applied using eye drops, gels, ointments, tissue glue, or contact lenses. The use of histatin accelerates the healing of corneal wounds and ocular surface disease compared to untreated wounds. The peptide fragment of histatin includes specific sequences such as SEQ. ID. NO. 1 through SEQ. ID. NO. 33. Overall, the patent provides a technical solution for promoting wound healing and treating ocular surface disease.

Problems solved by technology

These studies were all done in vitro and can not be translated to a finding for therapeutic or clinical use, especially since wound and disease healing are complex processes that need to be highly regulated in order to function properly.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0014]Histatins are naturally occurring oral peptides produced by humans and non-human primates that demonstrate direct anti-infective activity, potent anti-inflammatory properties, and stimulate epithelial wound healing in several tissue and organ culture systems. A research facility has developed a technique to isolate this natural substance, making it a potential topical treatment for wounds.

[0015]In a preferred embodiment, a peptide including at least one amino acid sequence of at least eight amino acids adjacently present in Histatin 1, 2, 3, and / or 5 is used to treat a corneal wound or ocular surface disease.

[0016]In one preferred embodiment, a method of treating corneal wounds includes the step of administering a therapeutic amount of at least a portion of a histatin peptide at a site of a corneal wound. In another preferred embodiment, a method of treating ocular surface disease includes the step of administering a therapeutic amount of at least a portion of a histatin pepti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

Histatins may be used for corneal wound healing and as a treatment for ocular surface disease in humans and other animals. For example, histatins could be included in eye drops, eye gels, ointment, glue, or embedded in (polymer) contact lenses.

Description

REFERENCE TO RELATED APPLICATIONS[0001]This application claims one or more inventions which were disclosed in Provisional Application No. 61 / 648,845, filed May 18, 2012, entitled “HISTATIN FOR CORNEAL WOUND HEALING AND OCULAR SURFACE DISEASE”. The benefit under 35 USC §119(e) of the United States provisional application is hereby claimed, and the aforementioned application is hereby incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The invention pertains to the field of wound and disease healing. More particularly, the invention pertains to corneal wound healing and treating ocular surface disease using histatins.[0004]2. Description of Related Art[0005]Histatins have been shown in in vitro studies to be wound healing agents from saliva. More specifically, WO 2009 / 087117 (and its US equivalent US Patent Publication 2011 / 0178010), herein incorporated by reference, identified peptides of histatin, which had wound healing properties in vit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/17A61K38/08A61K38/10
CPCA61K38/1709A61K38/10A61K38/08A61K9/0048A61P27/02A61K9/0051
Inventor SAMBURSKY, ROBERT P.VANDINE, ROBERT W.CONDON, PETER
Owner VISUS THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com